Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Range Cancer Therapeutics ETF CNCR

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The... see more

Bullboard (NDAQ:CNCR)

View:
Post by vitreum3on Jun 02, 2016 10:53am

Immunotherapy ETF

This company owns a basket of immunotherapy drug cos. The recent announcement of the universal cancer vaccine research in the UK should excite some interest. I have a small position.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities